In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle

Executive Summary

It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?

You may also be interested in...



Hamburg FDA May Look Favorably On Anti-infectives For Serious Conditions

Anti-infective drug developers may see new opportunities for a favorable regulatory review climate for products for a few serious conditions, based on FDA's public health-oriented top management team under new Commissioner Margaret Hamburg and Deputy Commissioner Joshua Sharfstein

Pacific Horizon: Encouraging Mutations in the Venture Model

Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks

Antibiotic Assistance

The drug safety/user fee bill working its way through Congress has some surprising benefits for antibiotic drug developers, and a voucher scheme to let companies developing drugs for tropical diseases earn the right to faster FDA reviews for more commercially attractive products.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel